Abstract Number: 1421 • ACR Convergence 2026
Rituximab for Inflammatory Ocular Disease in Rheumatoid Arthritis: A Systematic Review of Clinical Outcomes
Background/Purpose: Inflammatory ocular involvement in rheumatoid arthritis (RA) can lead to severe, sight-threatening complications and is often refractory to conventional immunosuppressive therapy. Rituximab (RTX) has…Abstract Number: 1637 • ACR Convergence 2026
Seeing an Alternative: The Role of Leflunomide in Autoimmune Eye Disease
Background/Purpose: Treatment options for autoimmune eye disease (AED) are limited. In patients with contraindications to MTX and restricted access to biologics, non-biologic DMARD options are…Abstract Number: 1639 • ACR Convergence 2026
The Relationship between Smoking, Uveitis and Vision Loss: A Retrospective Study Using TriNetX, a Global Database
Background/Purpose: Uveitis is an inflammatory eye disease associated with autoimmune disorders, infections, and smoking. While smoking is linked to greater disease severity and vision loss,…Abstract Number: 1745 • ACR Convergence 2026
Exploring the Risk of Ocular Adverse Events Associated with Janus Kinase Inhibitors: Analysis of the FDA Adverse Event Reporting System (FAERS)
Background/Purpose: Janus kinase (JAK) inhibitors are increasingly used for rheumatoid arthritis and other immune-mediated diseases. While cardiovascular, infectious, thromboembolic, and malignant adverse events have been…Abstract Number: 2075 • ACR Convergence 2026
Multi-Cytokine Profiles in Blood and Tears Predict Subclinical Disease Activity in Aqueous Humor of Patients with Chronic Autoimmune Uveitis
Background/Purpose: Autoimmune uveitis is an inflammatory disorder of the eye that is associated with significant morbidity, including vision-threatening complications and chronic reliance on immunosuppressive therapies.…Abstract Number: 2319 • ACR Convergence 2026
Axial Spondyloarthritis beyond the Spine in Latin America: One-Year Manifestation Patterns from the ESPALDA-PANLAR Registry
Background/Purpose: Axial spondyloarthritis (axSpA) is frequently accompanied by peripheral musculoskeletal (MSK) and extra-musculoskeletal (non-MSK) manifestations that influence prognosis and treatment. However, longitudinal data on their…Abstract Number: 2496 • ACR Convergence 2026
Examining the Risk of Pediatric Uveitis Relapse After Discontinuation of Long-Term Systemic Immunosuppressive Therapy in a Retrospective Cohort
Background/Purpose: Autoimmune uveitis is a chronic, relapsing condition that carries risk of long-term visual impairment and often requires prolonged systemic immunosuppressive therapy (IMT). ACR guidelines recommend two years of sustained disease control before tapering therapy. Previous studies report high…Abstract Number: 2508 • ACR Convergence 2026
Relationship Between Anti‑TNF Drug Levels, Anti‑Drug Antibodies, and Disease Activity in Uveitis With or Without JIA: A Single-Center Descriptive Study
Background/Purpose: Anti-TNF therapy such as adalimumab (ADAL) or infliximab (IFX) is commonly used to treat patients with uveitis and/or juvenile idiopathic arthritis (JIA). Variability in…Abstract Number: 2513 • ACR Convergence 2026
Stratifying Risk of Uveitis Among Patients with Oligoarticular or Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: Uveitis is a vision-threatening complication of juvenile idiopathic arthritis (JIA). Younger age and antinuclear antibody (ANA) positivity are established risk factors for the development…Abstract Number: 2611 • ACR Convergence 2026
Clinical Presentation, Treatment, and Outcomes of Idiopathic Inflammatory Orbital Myositis: A Systematic Review and Individual Patient Data Meta-analysis
Background/Purpose: Idiopathic inflammatory orbital myositis (IIOM) is a rare inflammatory disorder of the extraocular muscles without an identifiable secondary cause. Evidence is limited to case…Abstract Number: 0105 • ACR Convergence 2026
Gene expression signatures as predictors of response to methotrexate in pediatric non-infectious uveitis (NIU).
Background/Purpose: Methotrexate (MTX) is the recommended first-line treatment for children with non-infectious uveitis (NIU), with treatment failure rates as high as 50%. Because therapeutic response…Abstract Number: 2630 • ACR Convergence 2026
Immunological Heterogeneity in Ocular and Systemic Sarcoidosis: Insights from Biopsy-Proven Disease
Background/Purpose: Ocular features of sarcoidosis include uveitis, adnexal masses, and keratoconjunctivitis sicca. Although linked by a common granulomatous pathology, the multisystem manifestations of sarcoidosis exhibit…Abstract Number: 0411 • ACR Convergence 2026
Association of Two Tear Inflammatory Biomarkers, MMP-9 and Osmolarity, with Minor Salivary Gland Biopsy Positivity and Ocular Surface Damage in Primary Sjögren’s Disease.
Background/Purpose: Sjögren's Disease (SjD) is frequently complicated by dry eye disease (DED), tear film instability, and ocular surface inflammation. MSG biopsy is important for classification…Abstract Number: 2637 • ACR Convergence 2026
Predominance of HLA-B35 and HLA-B40 Over HLA-B27 in a Colombian Cohort of Patients With Non-Infectious Uveitis
Background/Purpose: Non-infectious uveitis is a major cause of visual impairment worldwide and is influenced by genetic factors that contribute to disease susceptibility and phenotype. HLA-B27…Abstract Number: 0588 • ACR Convergence 2026
The Updated Sos Project: To Switch Or To Swap After the first TnfA Failure For Childhood Non-Infectious Uveitis
Background/Purpose: Twenty-five% of patients with Childhood chronic non-infectious uveitis (cNIU) do not achieve disease remission. In this setting, there is no consensus whether switching to…
ACR Meeting Abstracts